effectiveness and safety of bushen culuan decoction for anovulatory infertility

Conditions: Anovulatory Infertility; Abnormal Uterine Bleeding-Ovulatory Disorders; Polycystic Ovarian Syndrome; Hyperprolactinemia; Luteinized Unruptured Follicle Syndrome; Corpus Luteum Insufficiency; Ovarian Insufficiency

Summary: this study is to evaluate the effectiveness and safety of bushen culuan decoction in the treatment of anovulatory infertility, including anovulatory abnormal uterine bleeding, polycystic ovarian syndrome, hyperprolactinemia, luteinized unruptured follicle syndrome, corpus luteum insufficiency and ovarian insufficiency, through a randomised, double-blinded, double-dummy, parallel positive controlled, adaptive multicenter clinical trial.

anovulation is one of the main causes of female infertility. anovulatory infertility account for a proportion of 25-30% in whole female infertility. in western medicine, hormone induced ovulation and assisted reproduction technology are two main ways to solve the problem and clomiphene citrate is the first-line medication in ovulation induction. there are many side effects being reported in the treatment with modern medicine technique such as ovarian hyperstimulation syndrome, complication with uteroscope and puncture egg retrieval, low pregnancy rate with high ovulation rate, potential cancer occuring risk and offspring healthy risk. bushen culuan decoction is a traditional chinese medicine recipe with 10 chinese herbs including tusizi, yinyanghuo, xianmao, xuduan, gouqizi, nvzhenzi, zelan, shengpuhuang, xiangfu and chuanshanlong. previous laboratory and exploratory clinical researches have proved bushen culuan decoction had an exactly efficacy in treating anovulatory infertility safely. in the first stage, the primary sample size in the study is 528. half patients will receive bushen culuan decoction and clomiphene citrate placebo, while the other half will receive clomiphene citrate tablets and bushen culuan decoction placebo. when 1/3 of 528 patients complete the treatment, we will analysis the treatment efficacy of 6 diseases separately, and find which of them could be the target diseases of bushen culuan decoction. then we will modify the sample size depending on the result in first stage, and the research will only be processed in the target diseases being chosen. in the next stage, half patients will receive bushen culuan decoction and clomiphene citrate placebo, while the other half will receive clomiphene citrate tablets and bushen culuan decoction placebo.

Eligibility criteria:
inclusion criteria: 1. aged 21\~40 years old; 2. diagnosed with infertility; 3. diagnosed with one of below diseases: anovulatory abnormal uterine bleeding, polycystic ovarian syndrome, hyperprolactinemia, luteinized unruptured follicle syndrome, corpus luteum insufficiency and ovarian insufficiency, 4. diagnosed with tcm syndrome of kidney deficiency and blood stasis syndrome; 5. patients who has normal sexual intercourse during treatment; 6. voluntary to sign the informed consent. exclusion criteria: 1. infertility due to congenital physiological defect or malformation; 2. infertility due to hereditary factors； 3. infertility due to oviduct defect, immune factors, uterine fibroid, adenomyosis, endometriosis or hypoplasia of uterus； 4. spouse has reproductive defects； 5. severe abnormity of cardiovascular system, liver function, kidney function or hemopoietic system； 6. allergy to experimental drugs

Keywords: anovulatory infertility bushen culuan decoction